In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intra-Cellular Therapies, Inc.

http://www.intracellulartherapies.com

Latest From Intra-Cellular Therapies, Inc.

Otsuka Counts The Cost Of Alzheimer’s Agitation Fail

The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.

Clinical Trials Neurology

Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT

Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.

Clinical Trials Strategy

Schizophrenia, Depression And Neuropathy: What’s Coming In 2024

The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem. 

Approvals Neurology

Latuda Enters ‘Twilight’ Phase Pending Generic Competition

A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.

Generic Drugs Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register